Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, is FDA-approved for obesity related to BBS and has demonstrated significant improvements in appetite control and weight outcomes in clinical trials [[6], [7], [8]]. This evidence concerns the gene MC4R and obesity disorder.